Website: N/A
Stock Symbol: NASDAQ: IMGN
Market Value: N/A (in millions)
In this Annual Report on Form 10-K, ImmunoGen, Inc. (ImmunoGen, Inc., together
with its subsidiaries, is referred to in this document as we, us, ImmunoGen, or
the Company), incorporates by reference certain information from parts of other
documents filed with the Securities and Exchange Commission. The Securities and
Exchange Commission allows us to disclose important information by referring to
it in that manner. Please refer to all such information when reading this Annual
Report on Form 10-K. All information is as of June 30, 2006 unless otherwise
indicated. For a description of the risk factors affecting or applicable to our
business, see “Risk Factors,” below.
The Company
We develop novel, targeted therapeutics for the treatment of cancer using our
expertise in cancer biology, monoclonal antibodies (antibodies), and small
molecule cell-killing (cytotoxic) agents.